CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
NCT02027935
Completed
This phase II trial studies the side effects and how well white blood cells taken from person's own (autologous) cluster of differentiation (CD)8+ antigen-specific T cells, cyclophosphamide, aldesleukin, and ipilimumab work in treating patients with melanoma that has spread to another place in the body. Autologous CD8+ antigen-specific T cells are white blood cells that are designed in the laboratory to find melanoma cells and may kill them. Biological therapies, such as aldesleukin, use substan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Register for Updates
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies
NCT02419495
Terminated
This phase Ib trial studies the side effects and best dose of selinexor when given together with several different standard chemotherapy or immunotherapy regimens in treating patients with malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Selinexor may stop the growth of cancer cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: MD Anderson in The Woodlands, Conroe, Texas +4 locations
Conditions: Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
Register for Updates
A Phase 1 Study of ADI-001 in B Cell Malignancies
NCT04735471
Active Not Recruiting
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: Stanford University Medical Center, Stanford, California +9 locations
Conditions: Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin, Primary Mediastinal B-cell Lymphoma
Register for Updates
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
NCT00336024
Active Not Recruiting
This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma when given before additional intense chemotherapy followed by peripheral blood stem cell rescue. It is not yet known which combination chemotherapy regimen is more effective when given before a peripheral stem cell transplant in treating supratentorial... Read More
Gender:
ALL
Ages:
2 years and below
Trial Updated:
09/16/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +144 locations
Conditions: Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor, Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified
Register for Updates
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
NCT02623972
Active Not Recruiting
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Register for Updates
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
NCT04715191
Recruiting
Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CARE T cells, a new experimental treatment. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that pro... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
09/16/2024
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor
Register for Updates
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
NCT04088890
Active Not Recruiting
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Stanford Medical Center, Stanford, California
Conditions: B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B
Register for Updates
A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine
NCT01088789
Active Not Recruiting
The purpose of this study is to evaluate the safety and feasibility of long term boost vaccination of a lethally irradiated, allogenic pancreatic tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene alone or given in combination with either a single intravenous dose or daily metronomic oral doses of cyclophosphamide for the treatment of patients with surgically resected adenocarcinoma of the head, neck, tail or the uncinate process of the pancrea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2024
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
GFRα4 CAR T Cells in MTC Patients
NCT04877613
Recruiting
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFRα4 with tandem TCR/CD3ζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-GFRa4 cells") in patients with incurable medullary thyroid cancer (MTC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Metastatic Medullary Thyroid Cancer, Recurrent Thyroid Gland Medullary Carcinoma
Register for Updates
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
NCT04187898
Completed
The purpose of this study is to compare the effect of Eflapegrastim on duration of neutropenia in patients with early-stage breast cancer when administered at varying intervals following Docetaxel and Cyclophosphamide administration.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
09/10/2024
Locations: ACRC/ Arizona Clinical Research Center, Tucson, Arizona +7 locations
Conditions: Neutropenia, Breast Cancer
Register for Updates
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
NCT06245889
Recruiting
Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will be performed after treatment completion. Patients with complete clinical response will proceed to surgery. Patients with clinical residual disease will complete neoadjuvant rescue with 4 cycles of doxorubicin/cyclophosphamide prior to surgery. If residual disea... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland +1 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
NCT03995147
Active Not Recruiting
This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: The University of Chicago, Chicago, Illinois
Conditions: B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Register for Updates